Who leads the market of 70 billion children's drugs

According to the latest 2017 national economic and Social Development Statistics Bulletin released by the National Bureau of statistics on February 28, 2018, the number of 0-15-year-old children in China has reached 247 million, accounting for 17.80% of the total population of the country The number of paediatricians and the market of children's drugs have become a hot topic since the new birth policy was announced Overview children's drug approval increased by nearly 9% According to the data on the official website of the State Food and drug administration, there are 2587 production registration approvals for drugs named "children", an increase of 8.74% compared with 2016 Among them, the approval of pediatric drugs accounted for 40%, and the production approval of pediatric Chinese patent medicine accounted for 60% In addition, there are drugs not named "children" for the treatment of common and frequently occurring diseases in children There are more than 3000 production approvals, accounting for about 6% of the total number of production approvals issued by the State Drug Administration It is well known that cough and cold medicines account for more than 40% of children's medicines The common and frequent diseases of children with normal growth and development are mainly cold, cough and gastrointestinal diseases Among them, cold is a common and frequent disease in four seasons Especially in summer, the indoor and outdoor temperature difference caused by air conditioning is easy to cause cold and fever, tonsillitis, pharyngitis and various fever diseases Anti cold, cough and bronchitis drugs have become the main products in children's drug market According to the data of mienei.com, in 2016, the market scale of Chinese children's drug use reached 65.197 billion yuan, and it is expected to exceed 70 billion yuan in 2017, of which the drug use for cold, cough and gastrointestinal diseases accounted for the main share Generally speaking, in the children's drug market, the hot selling categories are relatively concentrated, among which cough and cold drugs account for more than 40% At present, the amount of top 10 drugs is 151 million yuan Most of the drugs for children's cold and cough are compound preparations Among 32 children's cold and cough drugs in public hospitals in key cities in China, only 9 are single prescriptions, and the compound preparations account for more than 70% The combination of different mechanisms of action has become the main diagnosis and treatment of children's cold and cough According to the data of minenet, in 2017, there were 26 main varieties of drugs for children's cold and cough in public hospitals in key cities in China, with the amount of drugs nearly 300 million yuan The top 10 drugs are: ambroxol oral solution, Pediatric Paracetamol Huang Namin granules, paracetamol mamei pediatric dry suspension, yuphene methylphenamine granules, meimin pseudoephedrine oral solution, pseudoephedrine pediatric drops, aminocaffeine Huang Min solution, paracetamol mamei dry suspension, phenol mamei min oral solution, compound formodine solution The amount of top 10 drugs was 151 million yuan, an increase of 13.62% over the previous year It is estimated that the amount of cough medication for children's Ganmaoling in the retail market of public medical institutions and pharmacies in China will reach 5 billion yuan Ambroxol is the first compound preparation of respiratory In 2004, ambroxol compound preparation of Beijing Hanmei was approved to be listed in China It is the exclusive product in the domestic market, including tablet and oral solution, and the trade name is etanjin Ambroxol and clenbuterol were used in the compound preparation of ambroxol and clenbuterol Ambroxol, as a mucolysis agent, can increase the secretion of serous gland of respiratory mucosa, reduce the secretion of mucus gland, reduce the viscosity of sputum, promote the secretion of pulmonary surfactant, increase the movement of bronchial cilia, and make the sputum easy to cough up Clenbuterol is a selective receptor agonist, which can relax the smooth muscle of bronchus, enhance the movement of cilia, dissolve mucus and promote the discharge of sputum This product is suitable for cough, viscous sputum, dysphagia, wheezing and other syndromes caused by acute and chronic respiratory diseases after cold According to the data of mienei.com, in 2017, the amount of ambroxol used in public hospitals in key cities in China reached 29.02 million yuan, an increase of 21.33% over the previous year, showing a steady growth trend Xiaoer aminophenol huangnamin granules, the leading retail market of Xiaoer aminophenol huangnamin granules, is a compound preparation composed of paracetamol, chlorphenamine maleate and artificial bezoar, which is suitable for relieving the symptoms of fever, headache, limb ache, sneezing, runny nose, nasal obstruction and sore throat caused by children's common cold and influenza At present, China has approved 376 approval documents for the production of paediatric paracetamol Huang Namin, mainly including granules and tablets, which are mainly used clinically The production approval documents of Xiaoer paracetamol huangnamin granules accounted for 69.68% of the total, which were held by 262 enterprises and distributed in more than 20 provinces and cities in China The top 5 provinces are Hebei, Sichuan, Shanxi, Hubei and Jiangxi, with a total of 153, accounting for 58% of the production approval manufacturers According to the data of mienei.com, in 2017, the amount of Pediatric Paracetamol and huangnamin used in public hospitals in key cities in China was 22.55 million yuan, with a year-on-year growth rate of 55.87% The top 3 manufacturers in the sample hospital market are Angel yeast (85.76%), Hunan HENGWEI (10.32%), Xinjiang Tongrentang health (3.15%), and many other manufacturers (0.77%) Paediatric aminopheniramine is the first paediatric cold drug in the retail market of drugstores in key cities in China In 2016, the sales volume of paediatric aminopheniramine in drugstores in key cities in China exceeded 220 million yuan, an increase of 15.96% over the previous year The top 5 manufacturers in the sample city retail market are: China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd accounts for 42.84%, Zhejiang Yafeng Pharmaceutical Co., Ltd accounts for 12.53%, Harbin Pharmaceutical Co., Ltd accounts for 6.09%, Angel yeast Pharmaceutical Co., Ltd accounts for 5.16%, sunflower Pharmaceutical Co., Ltd (Hengshui) accounts for 4.19% Market fluctuation of aminophenol and ephedrine is an oral syrup listed in 1996 in China Its main ingredients are paracetamol, pseudoephedrine hydrochloride and Dextromethorphan Hydrobromide Its trade name is Xiaobai It is the main product of Qidong branch of Bayer medical and health care Co., Ltd It is suitable for relieving fever, headache, aching limbs, sneezing, runny nose, stuffy nose, cough, sore throat and other symptoms caused by children's common cold and influenza After the expiration of the protection period of aminophenol and ephedrine, in 2008, the aminophenol and ephedrine syrup of Jiangxi Yaodu Renhe Pharmaceutical Co., Ltd., Harbin Taihua Pharmaceutical Co., Ltd and Jiangsu Hengrui Pharmaceutical Co., Ltd was listed The drug components were 16 mg paracetamol per ml, 1.5 ml pseudoephedrine hydrochloride and 0.5 mg dextromethorphane hydrobromide In 2009, Zhejiang Kant pharmaceutical group approved the listing of aminophenol and ephedrine suspension, each containing 80 mg paracetamol, 7.5 mg pseudoephedrine hydrochloride and 2.5 mg Dextromethorphan Hydrobromide The suspension of aminophenol and mamei has the characteristics of no central sedative and excitatory components, relatively small dosage, and strong taste adaptability, so it has gradually formed an advantage in the market Zhejiang Kant Pharmaceutical Co., Ltd.'s aminophenol and mamei dry suspension has a general agency mode in many provinces in China, and its propaganda is strong, with a trend of rising stars According to the data of mienei.com, in 2017, the amount of aminophenol and mamei suspension used in public hospitals in key cities in China was 21.97 million yuan, a decrease compared with the amount of 23.43 million yuan in the previous year Yuphenmethylmanamin increased 91.92% Yuphenmethylmanamin was used for bronchial congestive cough and expectoration caused by cold and bronchitis At present, three domestic enterprises have been approved to produce yuphene methylphenamine, mainly including the syrupy "seconium" of stard Pharmaceutical (Beijing), the granule "aikaiping" of Hainan Kaijian pharmaceutical and the dispersible tablet "silk" of Shenzhen Zhonglian pharmaceutical Yuphenmethylmanamin is a rapidly growing variety in recent years, which is used in different doses for children under 1 to 12 years old According to the data of mienei.com, in 2017, the amount of yuphene, methylphenamine granules used in public hospitals in key cities in China reached 20.29 million yuan, an increase of 91.92% over the previous year, with a remarkable growth rate Aikaiping, a granule of Hainan Kaijian pharmaceutical, accounts for 87.24% of the market of public hospitals in key cities, while secospinium, a syrup of Stade Pharmaceutical (Beijing), accounts for 12.76% The growth rate of pseudoephedrine drops is more than 20% Pseudoephedrine nasal drops for children is a product of Shanghai Johnson & Johnson Pharmaceutical Co., Ltd and its trade name is AI Chang Pseudoephedrine is used for symptomatic treatment of nasal obstruction, runny nose, cough and other symptoms caused by cold, hay fever or other upper respiratory allergies in infants Pseudoephedrine hydrochloride in this compound is a kind of adrenergic drug, which can constrict the blood vessels of nasal mucosa and relieve the symptoms of nasal congestion; Dextromethorphan Hydrobromide is a antitussive drug, which has antitussive effect by inhibiting the cough center of medulla oblongata According to minenet data, in 2017, the amount of pseudoephedrine nasal drops for children in public hospitals in key cities in China was 6.91 million yuan, an increase of 22.98% over the previous year It is worth mentioning that many countries in the world stipulate that OTC cold medicine should not be used for children under the age of 4 unless advised by doctors The key is to strengthen vaccination against cold and influenza viruses After the restriction of antibiotics and fluoroquinolones in China, the market structure of children's cold and cough drugs has changed With the enhancement of health care awareness of Chinese residents, the new concept of improving children's immunity is promoting the change of children's drug market.